Have your own idea? Try our Stock Screener
Norwegian (OSEAX) Biotech Industry Analysis
UpdatedJun 03, 2025
DataAggregated Company Financials
Companies11
- 7D-10.2%
- 3M-3.5%
- 1Y-59.1%
- YTD-14.3%
Over the last 7 days, the Biotech industry has dropped 10%, driven by a pullback from Nykode Therapeutics of 43%. Meanwhile, EXACT Therapeutics actually outperformed within the industry, gaining 13% in the last week. The industry has fallen 59% in the last year. Looking forward, earnings are forecast to grow by 45% annually.
Industry Valuation and Performance
Has the Norwegian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 03 Jun 2025 | NOK 4.6b | NOK 884.9m | -NOK 744,173,229.44 | 191.5x | -6.2x | 5.2x |
| Thu, 01 May 2025 | NOK 4.6b | NOK 519.6m | -NOK 1,017,758,323.79 | 111x | -4.6x | 8.9x |
| Sat, 29 Mar 2025 | NOK 4.6b | NOK 520.4m | -NOK 918,625,294.70 | 110.1x | -5x | 8.8x |
| Mon, 24 Feb 2025 | NOK 5.4b | NOK 471.9m | -NOK 1,118,042,899.80 | 127.5x | -4.8x | 11.4x |
| Wed, 22 Jan 2025 | NOK 5.1b | NOK 457.4m | -NOK 1,071,726,087.74 | 153.4x | -4.7x | 11.1x |
| Fri, 20 Dec 2024 | NOK 4.6b | NOK 458.1m | -NOK 1,077,576,134.56 | 150.3x | -4.2x | 9.9x |
| Sun, 17 Nov 2024 | NOK 3.5b | NOK 484.0m | -NOK 1,065,358,188.10 | 150.5x | -3.3x | 7.3x |
| Tue, 15 Oct 2024 | NOK 5.1b | NOK 470.4m | -NOK 1,060,957,315.60 | 57.6x | -4.8x | 10.8x |
| Thu, 12 Sep 2024 | NOK 5.3b | NOK 471.5m | -NOK 1,060,384,624.80 | 60.3x | -5x | 11.2x |
| Sat, 10 Aug 2024 | NOK 8.1b | NOK 516.1m | -NOK 1,050,018,160.78 | 69.8x | -7.7x | 15.6x |
| Mon, 08 Jul 2024 | NOK 8.6b | NOK 512.7m | -NOK 1,037,768,038.42 | 68x | -8.3x | 16.7x |
| Wed, 05 Jun 2024 | NOK 9.3b | NOK 640.9m | -NOK 938,430,438.17 | 38.5x | -10x | 14.6x |
| Fri, 03 May 2024 | NOK 8.5b | NOK 659.9m | -NOK 961,422,368.96 | 36.1x | -8.8x | 12.9x |
| Sun, 31 Mar 2024 | NOK 9.2b | NOK 658.4m | -NOK 943,969,556.56 | 40.9x | -9.8x | 14x |
| Tue, 27 Feb 2024 | NOK 15.0b | NOK 672.0m | -NOK 1,003,915,063.52 | 40x | -15x | 22.4x |
| Thu, 25 Jan 2024 | NOK 16.5b | NOK 656.7m | -NOK 1,359,907,814.00 | 58.8x | -12.2x | 25.2x |
| Sat, 23 Dec 2023 | NOK 15.8b | NOK 653.0m | -NOK 1,349,168,252.00 | 60.5x | -11.7x | 24.3x |
| Mon, 20 Nov 2023 | NOK 15.2b | NOK 656.9m | -NOK 1,368,314,717.00 | 55.5x | -11.1x | 23.2x |
| Wed, 18 Oct 2023 | NOK 14.8b | NOK 627.7m | -NOK 1,466,596,809.00 | 48.1x | -10.1x | 23.5x |
| Fri, 15 Sep 2023 | NOK 15.3b | NOK 624.8m | -NOK 1,460,298,518.00 | 56.3x | -10.5x | 24.5x |
| Sun, 13 Aug 2023 | NOK 16.4b | NOK 558.1m | -NOK 1,464,292,193.00 | 52.5x | -11.2x | 29.4x |
| Tue, 11 Jul 2023 | NOK 15.1b | NOK 559.1m | -NOK 1,468,303,798.00 | 59.7x | -10.3x | 26.9x |
| Thu, 08 Jun 2023 | NOK 17.2b | NOK 565.0m | -NOK 1,501,685,933.00 | 65.2x | -11.4x | 30.4x |
| Sat, 06 May 2023 | NOK 16.7b | NOK 522.6m | -NOK 1,456,245,457.00 | 55.3x | -11.5x | 31.9x |
| Mon, 03 Apr 2023 | NOK 15.4b | NOK 549.2m | -NOK 1,547,316,135.00 | 32.9x | -10x | 28.1x |
| Wed, 01 Mar 2023 | NOK 17.1b | NOK 829.7m | -NOK 1,435,924,950.00 | 31.7x | -11.9x | 20.6x |
| Fri, 27 Jan 2023 | NOK 17.9b | NOK 808.8m | -NOK 1,394,183,901.00 | 24.3x | -12.9x | 22.2x |
| Sun, 25 Dec 2022 | NOK 19.8b | NOK 807.8m | -NOK 1,393,657,281.00 | 40x | -14.2x | 24.5x |
| Tue, 22 Nov 2022 | NOK 18.1b | NOK 836.1m | -NOK 1,335,833,689.00 | 36.6x | -13.6x | 21.7x |
| Thu, 20 Oct 2022 | NOK 17.4b | NOK 814.2m | -NOK 1,364,880,946.00 | 35.9x | -12.8x | 21.4x |
| Sat, 17 Sep 2022 | NOK 19.0b | NOK 799.1m | -NOK 1,369,244,939.00 | 35.8x | -13.9x | 23.8x |
| Mon, 15 Aug 2022 | NOK 22.8b | NOK 759.3m | -NOK 1,378,203,280.00 | 47.6x | -16.5x | 30x |
| Wed, 13 Jul 2022 | NOK 19.9b | NOK 781.5m | -NOK 1,384,232,766.00 | 45.6x | -14.3x | 25.4x |
| Fri, 10 Jun 2022 | NOK 22.3b | NOK 1.1b | -NOK 1,032,396,816.00 | 40.9x | -21.6x | 20.5x |
Price to Earnings Ratio
-21.6x
Current Industry PE
- Investors are pessimistic on the Norwegian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 19.6x is higher than the industry's current PS ratio of 5.2x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 6.7% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the Norwegian Healthcare industry?
| NO Market | 0.24% | |
| Healthcare | -3.92% | |
| Biotech | -10.17% | |
| Biotech | -10.17% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABS Arctic Bioscience | NOK 3.02 | 4.9% +NOK 3.8m | -69.5% | PS1.8x |